

Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children

Nicole Ullrich¹, Sanjay Prabhu², Roger Packer³, Stewart Goldman⁴, Nathan Robison⁵, Jeffrey Allen⁶, David Viskochil⁷, David Gutmann⁸, John Perentesis⁹, Bruce Korf¹⁰, Michael Fisher¹¹, and Mark Kieran¹²

¹Children's Hospital Boston

²Boston Children's Hospital

³Children's National Health System

⁴Ann & Robert H Lurie Children's Hospital of Chicago

⁵Children's Hospital Los Angeles, University of Southern California Keck School of Medicine

⁶NYU Langone Health

⁷University of Utah

⁸Washington University in Saint Louis School of Medicine

⁹Childrens Hospital Medical Center

¹⁰University of Alabama at Birmingham

¹¹Children's Hospital of Philadelphia

¹²Dana-Farber Cancer Institute

October 13, 2020

Abstract

Data for visual acuity (VA) after treatment of neurofibromatosis type 1-associated optic pathway gliomas (NF1-OPGs) is limited. We retrospectively collected VA, converted to logMAR, before and after targeted therapy with everolimus for NF1-OPG, and compared to radiologic outcomes (14/18 with NF1-OPG, 25 eyes [3 without quantifiable vision]). Upon completion of treatment, VA was stable in 19 eyes, improved in 4 eyes, and worse in 2 eyes; visual and radiologic outcome were discordant. In summary, the majority of children with NF1-OPG exhibited stabilization of their VA after everolimus treatment. A larger, prospective study will help delineate visual outcomes after targeted therapy.

Hosted file

Visual outcome after everolimus final (2).pdf available at <https://authorea.com/users/355327/articles/486406-visual-outcomes-following-everolimus-targeted-therapy-for-neurofibromatosis-type-1-associated-optic-pathway-gliomas-in-children>

Hosted file

Table 1 patient demographics.pdf available at <https://authorea.com/users/355327/articles/486406-visual-outcomes-following-everolimus-targeted-therapy-for-neurofibromatosis-type-1-associated-optic-pathway-gliomas-in-children>

Hosted file

Table 2 visual and radiologic outcomes.pdf available at <https://authorea.com/users/355327/articles/486406-visual-outcomes-following-everolimus-targeted-therapy-for-neurofibromatosis-type-1-associated-optic-pathway-gliomas-in-children>